HBP Share Price | Helix BioPharma Corp. Stock Analysis & Recommendation

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

636

Shareholding (Apr 2014)

FII

0.00%

Held by 2 FIIs

DII

100.0%

Held by 0 DIIs

Promoter

0.00%

Compare Helix BioPharma Corp. with Similar Stocks

Satellos Bioscience, Inc.Theratechnologies, Inc.Medexus Pharmaceuticals, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

CAD 164 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.01

Return on Equity

-30.36%

Price to Book

10.22

Revenue and Profits:

Net Sales:

(Quarterly Results - Apr 2025)

Net Profit:

-2 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

114.77%

6 Months

117.24%

1 Year

75.81%

2 Years

84.39%

3 Years

68.0%

4 Years

-57.05%

5 Years

-55.0%

Helix BioPharma Corp. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

8.07%

EBIT to Interest (avg)

-24.86

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

0.51

Sales to Capital Employed (avg)

Tax Ratio

3.38%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

0.58%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

-95.36

EV to EBIT

-13.55

EV to EBITDA

-13.57

EV to Capital Employed

-62.63

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

Negative BV

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bollinger Bands

Bearish

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Mildly Bullish

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Apr 2014

Shareholding Compare (%holding)

Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 2 Foreign Institutions (0.0%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Apr'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Apr 2025 is 0.00% vs 0.00% in Apr 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Apr 2025 is 16.67% vs -38.46% in Apr 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Apr'25",
        "Apr'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-1.50",
          "val2": "-1.80",
          "chgp": "16.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-1.50",
          "val2": "-1.80",
          "chgp": "16.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Jul'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Jul 2024 is 0.00% vs 0.00% in Jul 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Jul 2024 is -47.62% vs 4.55% in Jul 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jul'24",
        "Jul'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-9.40",
          "val2": "-6.40",
          "chgp": "-46.87%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-9.30",
          "val2": "-6.30",
          "chgp": "-47.62%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Apr'25 - YoY

Apr'25

Apr'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-1.50

-1.80

16.67%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-1.50

-1.80

16.67%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Apr 2025 is 0.00% vs 0.00% in Apr 2024

Consolidated Net Profit

YoY Growth in quarter ended Apr 2025 is 16.67% vs -38.46% in Apr 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Jul'24

Jul'24

Jul'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-9.40

-6.40

-46.87%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-9.30

-6.30

-47.62%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Jul 2024 is 0.00% vs 0.00% in Jul 2023

Consolidated Net Profit

YoY Growth in year ended Jul 2024 is -47.62% vs 4.55% in Jul 2023

All Annual Results

Company CV

About Helix BioPharma Corp.

Helix BioPharma Corp.

Pharmaceuticals & Biotechnology

Helix BioPharma Corp. is an immuno-oncology company, which specializes in the field of cancer therapy. The Company is developing products for the prevention and treatment of cancer based on its technologies. The Company's product development initiatives are focused primarily on technologies that modulate the tumor microenvironment. The Company's technology platform, DOS47 yielded approximately two drug product candidates, L-DOS47 and vDOS47. L-DOS47 is an antibody protein conjugate where the urease component enzymatically converts naturally occurring urea to ammonia. L-DOS47 is under clinical study for the treatment of non-small cell lung cancer (NSCLC). L-DOS47 has completed preclinical testing and manufacturing development, following which, regulatory approvals are obtained in Poland and the United States to conduct Phase I/II and Phase I clinical studies. V-DOS47 is an antibody DOS47 conjugate that targets the vascular endothelial growth factor 2 receptor (VEGFR2).

Company Coordinates

Company Details

9120 Leslie St Suite 205 , RICHMOND HILL ON : L4B 3J9

Tel: 1 905 8412300

http://www.helixbiopharma.com

Registrar Details